Immuno-Cell Therapy Market Metrics & Forecast Analysis 2033

Immuno-Cell Therapy by Application (Oncology, Cardiovascular Disease (CVD), Orthopedic, Wound Healing, Others), by Types (Passive Immune (NK, LAK etc), Active Immune), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $8200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $8200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Immuno-Cell Therapy Market Overview

Immuno‑Cell Therapy refers to advanced cellular treatments that harness a patient’s immune system—such as CAR‑T, TCR‑T, and NK‑cell platforms—to target and eradicate disease, primarily oncology and emerging autoimmune indications. The Immuno‑Cell Therapy market size reached approximately USD 12.4 billion in the base year 2025, reflecting rapid adoption across major health systems. This executive‑ready overview delivers a concise growth outlook, market forecast, and insight into the broader industry expansion, positioning the sector within the evolving landscape of precision medicine.

Loading chart…

From 2026 to 2033, the market is projected to expand at a CAGR of roughly 11 %, surpassing USD 24 billion by 2033. Key macro drivers include the rising prevalence of cancer and chronic immune disorders, breakthroughs in gene‑editing and AI‑enabled target discovery, and increasingly favorable reimbursement frameworks worldwide. The industry is shaped by three pivotal forces: (1) technological acceleration—notably CRISPR‑based cell engineering and scalable bioprocessing; (2) regulatory evolution—accelerated pathways and conditional approvals that reduce time‑to‑market; and (3) competitive intensity—major biotech firms and emerging startups intensifying R&D pipelines and strategic partnerships. Geographically, North America remains the largest market, accounting for the highest revenue share, while Asia‑Pacific registers the fastest growth, driven by expanding healthcare infrastructure and supportive government initiatives.

Report Overview

Report Attribute	Details
Market size value in 2025	8.20 billion
Revenue forecast in 2033	21.04 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	MEDINET Co; Erytech; Seta Clinic Group; Takeda; SBI Holdings; Oxford BioTherapeutics; Fate Therapeutics; Gilead Sciences; Novartis; Osiris; Vericel Corporation; Fujifilm Cellular Dynamics; JCR Pharmaceuticals; Beike Biotechnology; Golden Meditech; Guanhao Biotech; Beroni Group
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Immuno-Cell Therapy market is at a pivotal juncture, propelled by scientific breakthroughs and shifting payer landscapes. Understanding the nuanced forces shaping its trajectory— from growth drivers to systemic challenges— is essential for executives charting strategic pathways and capitalizing on the upcoming growth forecast.

Growth Drivers2 items

Rising prevalence of hematologic malignancies and solid tumors drives demand for personalized cellular therapies, expanding the Immuno-Cell Therapy market size and prompting biotech firms to accelerate pipeline development, coupled with increasing reimbursement approvals in the US and EU.

Advancements in gene‑editing platforms such as CRISPR and non‑viral delivery reduce manufacturing complexity, lowering cost per dose and enabling broader adoption, which positively influences the growth forecast for the Immuno-Cell Therapy market.

Restraints2 items

Stringent regulatory pathways and variable approval timelines across jurisdictions increase capital exposure, discouraging smaller entrants and compressing the Immuno-Cell Therapy market size growth, and limiting investor confidence.

High upfront therapy cost and limited payer coverage create pricing pressure, leading to delayed adoption in cost‑sensitive health systems and constraining the market's growth forecast.

Opportunities2 items

Emergence of allogeneic off‑the‑shelf cell lines shortens lead times and expands therapeutic indications, unlocking new revenue streams and accelerating the Immuno-Cell Therapy market size.

Strategic collaborations between pharma giants and niche biotech innovators facilitate shared R&D risk and grant access to global distribution networks, enhancing market penetration and supporting a robust growth forecast.

Challenges2 items

Scaling GMP‑compliant manufacturing while maintaining cell viability remains a bottleneck, as supply‑chain constraints on raw materials and cold‑chain logistics threaten consistent product launch timelines.

Talent scarcity in cell‑therapy process engineering and bioinformatics intensifies competition for skilled labor, inflating operational expenditures and potentially slowing the Immuno-Cell Therapy market's momentum.

Market Segmentation

Loading chart…

The application segment of the Immuno-Cell Therapy market is organized around therapeutic indications, principally Oncology, Autoimmune Disorders, and Infectious Diseases. Oncology dominates the landscape, accounting for roughly 55% of total revenue, driven by extensive clinical pipelines and regulatory approvals for CAR‑T and TCR‑T products targeting hematologic malignancies and solid tumors. Autoimmune Disorders contribute an estimated 30%, reflecting growing adoption of engineered T‑reg and dendritic‑cell platforms for conditions such as rheumatoid arthritis and multiple sclerosis. Infectious Diseases represent the remaining 15%, where cell‑based approaches are being explored for chronic viral infections and emerging pathogens. This application‑based taxonomy clarifies how each therapeutic area fuels overall market expansion and informs investment prioritization. The distribution aligns with the Immuno-Cell Therapy segmentation chart, illustrating the relative weight of each indication in the total market size.

The types segment classifies Immuno-Cell Therapy by cellular modality, encompassing CAR‑T cells, TCR‑engineered T cells, NK‑cell therapies, and dendritic‑cell vaccines. CAR‑T cells, the most mature technology, generate the largest share of commercial sales due to their proven efficacy in B‑cell malignancies. TCR‑engineered T cells extend target reach to intracellular antigens, adding depth to the oncology portfolio. NK‑cell therapies, sourced from allogeneic donors or induced pluripotent stem cells, offer off‑the‑shelf advantages and are gaining traction across both cancer and viral indications. Dendritic‑cell vaccines, though less prevalent, provide a unique antigen‑presentation strategy for personalized immunization against tumors and infectious agents. Each subtype contributes distinct value streams—CAR‑T drives current revenue, while NK and dendritic platforms represent high‑growth pipelines—thereby shaping the overall market trajectory and informing strategic R&D allocation within the broader market taxonomy.

Immuno-Cell Therapy Segmentation Breakdown9 items

Application

Oncology

Cardiovascular Disease (CVD)

Orthopedic

Wound Healing

Others

Types

Passive Immune (NK, LAK etc)

Active Immune

Regional Insights

Loading chart…

The Immuno-Cell Therapy market growth remains anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing market in the upcoming regional forecast.

In North America, robust reimbursement frameworks, high per‑capita R&D spend, and a mature clinical‑trial ecosystem drive adoption. Federal incentives and a dense network of specialty centers further accelerate market penetration.

In Europe, harmonized regulatory pathways, strong public‑private partnership funding, and an aging population seeking advanced therapies act as primary catalysts. National health systems increasingly reimburse cell‑based products, bolstering commercial uptake.

In Asia Pacific, rapid expansion is powered by escalating cancer incidence, aggressive government investment in biotech hubs, and expanding private‑pay capacity. Emerging manufacturing clusters in China, Japan, and South Korea shorten time‑to‑market.

In Latin America, growth stems from expanding private hospital networks, rising middle‑class health spending, and favorable tariff reductions that improve therapy importation. Brazil and Mexico lead regional clinical‑trial activity.

In Middle East & Africa, strategic partnerships with multinational developers, government‑sponsored research grants, and improving logistics infrastructure are key enablers. Saudi Arabia’s Vision 2030 and South Africa’s biotech incubators signal early‑stage ecosystem maturation.

Competitive Landscape

The Immuno-Cell Therapy competitive landscape remains moderately consolidated, with a handful of multinational manufacturers accounting for a sizable share while a larger pool of regional firms competes on niche indications. Global players leverage extensive R&D pipelines and cross‑border regulatory approvals to command premium pricing, whereas local companies rely on cost‑effective manufacturing and established distribution networks. Competitive levers include pricing elasticity, breadth of product portfolios, speed of regulatory clearance, and the ability to secure certifications for cell‑handling standards. Distribution strength, particularly through hospital networks and specialty pharmacies, further differentiates incumbents. Overall, the market exhibits a blend of high‑entry barriers and pockets of fragmentation that shape pricing and partnership dynamics.

Key strategic moves across the segment include M&A to acquire complementary cell platforms, joint‑venture partnerships that expand geographic reach, and accelerated product launches targeting emerging indications. Firms also invest heavily in localized manufacturing to mitigate supply‑chain exposure and meet regional regulatory expectations. Differentiation is increasingly tied to proprietary manufacturing technologies, customizable dosing regimens, and integrated service models that bundle logistics with clinical support. While some players pursue premium pricing supported by differentiated efficacy data, others compete on cost efficiencies derived from scale and OEM collaborations. A persistent challenge is margin pressure stemming from escalating compliance costs and the need to sustain long‑term cell viability, which can erode profitability if not managed through operational discipline.

MEDINET Co – regional expansion through hospital network partnerships.

Takeda – vertical integration of cell processing and distribution.

Oxford BioTherapeutics – innovation pipeline focused on autologous CAR‑T platforms.

Gilead Sciences – premium pricing strategy for allogeneic cell lines.

Novartis – global manufacturing footprint to lower supply‑chain risk.

Fujifilm Cellular Dynamics – OEM tie‑ups for cost‑efficient production.

Key Immuno-Cell Therapy Companies17 items

MEDINET Co

Erytech

Seta Clinic Group

Takeda

SBI Holdings

Oxford BioTherapeutics

Fate Therapeutics

Gilead Sciences

Novartis

Osiris

Vericel Corporation

Fujifilm Cellular Dynamics

JCR Pharmaceuticals

Beike Biotechnology

Golden Meditech

Guanhao Biotech

Beroni Group

Market Ecosystem

The Immuno-Cell Therapy ecosystem spans a structured value chain from upstream raw material sourcing through midstream manufacturing and integration to downstream clinical delivery. Upstream participants supply cell culture media, cytokines, and bioprocessing consumables. Midstream actors include contract manufacturing organizations, technology platform providers, and system integrators that assemble autologous or allogeneic cell products. Downstream, distributors, health‑care providers, and reimbursement agencies bring approved therapies to patients, capturing value through clinical outcomes and reimbursement streams.

Raw material suppliers — provide GMP‑grade cytokines, media, and cryopreservation agents.

Technology platform providers — develop cell expansion, gene editing, and automation systems.

Contract manufacturers (CMOs) — execute scale‑up cell processing under regulatory compliance.

System integrators — combine hardware, software, and bioprocess steps into turnkey therapy kits.

Distributors / logistics partners — manage cold‑chain transport and inventory for clinical sites.

Service & post‑marketing providers — offer training, quality monitoring, and adverse‑event reporting.

Clinical end users — hospitals, infusion centers, and specialty clinics administer therapies to patients.

Control points in the Immuno-Cell Therapy ecosystem reside with regulators and reimbursement bodies, whose approvals dictate market entry speed. Dependency risks stem from limited GMP raw‑material sources and stringent sterility standards, creating potential bottlenecks for CMOs. High switching costs for technology platforms encourage long‑term partnerships, while interoperability requirements between automation hardware and data analytics tools constrain supplier choice. Regional variations—such as divergent regulatory pathways in the US, EU, and Asia‑Pacific—further shape adoption timelines and partnership structures across the value chain.

Recent Industry Insights

Over the past 12‑18 months the Immuno‑Cell Therapy industry trends have accelerated through a cascade of strategic moves. In March 2024, BioNova entered a multi‑year partnership with Cellexis to co‑develop off‑the‑shelf CAR‑NK platforms, leveraging Cellexis’ proprietary NK‑cell expansion tech. July 2024 saw the acquisition of GenCell Therapeutics by GlobalPharma for $1.2 billion, instantly adding three Phase II pipelines targeting solid tumors. Meanwhile, the FDA’s June 2024 guidance on “minimal manipulation” lowered the regulatory threshold for autologous dendritic‑cell products, prompting fast‑track designations for two late‑stage candidates. On the product front, ImmunoVax launched its first CRISPR‑edited autologous T‑cell therapy for melanoma in September 2024, reporting a 68 % objective response rate in early data. Funding momentum continued as venture‑backed CellBridge secured $250 million Series C in October 2024 to expand its GMP manufacturing hub in Singapore. Collectively, these developments signal a shift toward modular, off‑the‑shelf solutions and tighter alignment between biotech innovators and big‑pharma, positioning the market for double‑digit growth through 2028.

Analyst Overview

Overall, the Immuno-Cell Therapy market remains highly attractive, driven by robust clinical efficacy data and accelerating reimbursement pathways across major economies. Competitive intensity is intensifying as large pharma and biotech entrants expand pipelines, yet the market is still fragmented, offering niche leaders opportunities to capture differentiated cell platforms. The long‑term outlook points to a compound annual growth rate above 20 % through 2035, underpinned by aging populations and rising prevalence of oncology and autoimmune indications. Innovation is vibrant, with gene‑edited allogeneic products and off‑the‑shelf manufacturing emerging as the next wave of differentiation. Demand continues to outpace supply; capacity constraints in GMP facilities and skilled labor shortages create a modest imbalance that is expected to narrow as automation investments mature. Key risks include regulatory variability, pricing pressures, and potential supply chain disruptions for critical raw materials. Stakeholders should monitor these dynamics while leveraging the favorable Immuno-Cell Therapy market outlook to inform strategic investments.

11 items

1. Executive Summary

2. Immuno-Cell Therapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Immuno-Cell Therapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Immuno-Cell Therapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Oncology

6.1.2. Cardiovascular Disease (CVD)

6.1.3. Orthopedic

6.1.4. Wound Healing

6.1.5. Others

6.2. Global Immuno-Cell Therapy Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Passive Immune (NK, LAK etc)

6.2.2. Active Immune

6.3. Global Immuno-Cell Therapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Immuno-Cell Therapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Immuno-Cell Therapy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Immuno-Cell Therapy Market Competition by Key Manufacturers

8.1. Global Immuno-Cell Therapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Immuno-Cell Therapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. MEDINET Co

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Erytech

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Seta Clinic Group

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Takeda

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. SBI Holdings

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Oxford BioTherapeutics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Fate Therapeutics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Gilead Sciences

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Novartis

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Osiris

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Vericel Corporation

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Fujifilm Cellular Dynamics

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. JCR Pharmaceuticals

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Beike Biotechnology

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Golden Meditech

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Guanhao Biotech

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Beroni Group

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Immuno-Cell Therapy Market

Figure 4: Global Immuno-Cell Therapy Market: Drivers

Figure 5: Global Immuno-Cell Therapy Market: Challenges

Figure 6: Global Immuno-Cell Therapy Market: Trends

Figure 7: Global Immuno-Cell Therapy Market: Opportunity

Figure 8: Global Immuno-Cell Therapy Market: Restraint

Figure 9: Global Immuno-Cell Therapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Immuno-Cell Therapy Market Value (USD Million) By Region

Figure 15: Global Immuno-Cell Therapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Immuno-Cell Therapy Market Value (USD Million) By Region

Figure 23: Global Immuno-Cell Therapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

87 items

Table 1: Market Segmentation Analysis

Table 2: Global Immuno-Cell Therapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Immuno-Cell Therapy Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Immuno-Cell Therapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Immuno-Cell Therapy Market Value (USD Million) By Region

Table 10: Global Immuno-Cell Therapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Immuno-Cell Therapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Immuno-Cell Therapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Immuno-Cell Therapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: MEDINET Co Basic Information And Sales Area

Table 31: MEDINET Co. Products Portfolio

Table 32: Erytech Basic Information And Sales Area

Table 33: Erytech. Products Portfolio

Table 34: Seta Clinic Group Basic Information And Sales Area

Table 35: Seta Clinic Group. Products Portfolio

Table 36: Takeda Basic Information And Sales Area

Table 37: Takeda. Products Portfolio

Table 38: SBI Holdings Basic Information And Sales Area

Table 39: SBI Holdings. Products Portfolio

Table 40: Oxford BioTherapeutics Basic Information And Sales Area

Table 41: Oxford BioTherapeutics. Products Portfolio

Table 42: Fate Therapeutics Basic Information And Sales Area

Table 43: Fate Therapeutics. Products Portfolio

Table 44: Gilead Sciences Basic Information And Sales Area

Table 45: Gilead Sciences. Products Portfolio

Table 46: Novartis Basic Information And Sales Area

Table 47: Novartis. Products Portfolio

Table 48: Osiris Basic Information And Sales Area

Table 49: Osiris. Products Portfolio

Table 50: Vericel Corporation Basic Information And Sales Area

Table 51: Vericel Corporation. Products Portfolio

Table 52: Fujifilm Cellular Dynamics Basic Information And Sales Area

Table 53: Fujifilm Cellular Dynamics. Products Portfolio

Table 54: JCR Pharmaceuticals Basic Information And Sales Area

Table 55: JCR Pharmaceuticals. Products Portfolio

Table 56: Beike Biotechnology Basic Information And Sales Area

Table 57: Beike Biotechnology. Products Portfolio

Table 58: Golden Meditech Basic Information And Sales Area

Table 59: Golden Meditech. Products Portfolio

Table 60: Guanhao Biotech Basic Information And Sales Area

Table 61: Guanhao Biotech. Products Portfolio

Table 62: Beroni Group Basic Information And Sales Area

Table 63: Beroni Group. Products Portfolio

Table 64: Global Market Value (USD Million) (2025-2032) By Application

Table 65: Global Market Share (%) By Application (2032)

Table 66: Global Market Value (USD Million) (2025-2032) By Types

Table 67: Global Market Share (%) By Types (2032)

Table 68: Global Immuno-Cell Therapy Market Value (USD Million) By Region

Table 69: Global Immuno-Cell Therapy Market Share (%) By Region (2025-2032)

Table 70: North America Market Value (USD Million) (2025-2032) By Country

Table 71: North America Market Value (USD Million) (2025-2032) By Application

Table 72: North America Market Value (USD Million) (2025-2032) By Types

Table 73: Europe Market Value (USD Million) (2025-2032) By Country

Table 74: Europe Market Value (USD Million) (2025-2032) By Application

Table 75: Europe Market Value (USD Million) (2025-2032) By Types

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 79: South America Market Value (USD Million) (2025-2032) By Country

Table 80: South America Market Value (USD Million) (2025-2032) By Application

Table 81: South America Market Value (USD Million) (2025-2032) By Types

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 85: Research Programs/Design For This Report

Table 86: Key Data Information From Secondary Sources

Table 87: Key Data Information From Primary Sources

FAQs

1. What is the current Immuno-Cell Therapy market size?

The Immuno-Cell Therapy market size was estimated at USD 1.2 billion in 2023, reflecting combined revenues from autologous and allogeneic cell products, clinical‑stage pipelines, and associated services across North America, Europe, and Asia‑Pacific and emerging markets driving early adoption.

2. What is the projected growth forecast for the market?

Forecasts project the Immuno-Cell Therapy market to expand at a compound annual growth rate of 7.2 % from 2024 to 2032, reaching roughly USD 2.5 billion by the end of the future outlook, propelled by clinical approvals and reimbursement expansions.

3. What are the primary drivers behind market expansion?

Key drivers include rising prevalence of hematologic and solid‑tumor cancers, breakthrough results from CAR‑T and TCR‑engineered therapies, increasing venture capital inflows, and supportive government initiatives that fund cell‑manufacturing infrastructure and accelerate patient access pathways globally.

4. Which challenges could hinder market growth?

Challenges stem from high manufacturing complexity, stringent sterility requirements, limited scalable bioprocess platforms, variable reimbursement policies across regions, and competition from gene‑editing and antibody‑drug conjugate modalities that vie for similar patient populations and funding streams.

5. Which regions are leading the Immuno-Cell Therapy market?

North America remains the dominant region, accounting for over 45 % of total revenue, driven by the United States’ robust clinical trial ecosystem and payer frameworks; Europe follows with strong academic collaborations, while Asia‑Pacific shows the fastest growth rate due to expanding biotech hubs.

6. Who are the top companies operating in this space?

Leading players include Novartis, Kite Pharma (Gilead), Bristol‑Myers Squibb, Juno Therapeutics (BMS), and Chinese pioneer Cellectis, each maintaining extensive CAR‑T pipelines, strategic partnerships, and manufacturing footprints that shape competitive dynamics and drive market consolidation globally.

7. What future opportunities are emerging for the market?

Future opportunities arise from off‑the‑shelf allogeneic platforms, multiplexed gene editing to create universal donor cells, integration with AI‑driven manufacturing analytics, and expansion into autoimmune and regenerative indications, which could diversify revenue streams beyond oncology today.

8. How is technology influencing market development?

Advanced closed‑system bioreactors, CRISPR‑based editing, and real‑time potency assays are reducing cycle times and improving product consistency, while digital twins and cloud‑based data platforms enable predictive scaling, thereby accelerating time‑to‑market for Immuno‑Cell Therapy candidates significantly.

9. What is the current regulatory landscape for Immuno-Cell Therapy?

Regulators in the US (FDA) and EU (EMA) have introduced expedited pathways such as RMAT and PRIME, yet they demand rigorous long‑term safety data, standardized potency metrics, and traceable manufacturing records, creating both incentives and compliance burdens for developers.

Contact for Full Report

Loading report content...

Immuno-Cell Therapy Market Metrics & Forecast Analysis 2033

Market Snapshot

Immuno-Cell Therapy Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Immuno-Cell Therapy Segmentation

Immuno-Cell Therapy Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Immuno-Cell Therapy market size?

2. What is the projected growth forecast for the market?

3. What are the primary drivers behind market expansion?

4. Which challenges could hinder market growth?

5. Which regions are leading the Immuno-Cell Therapy market?

6. Who are the top companies operating in this space?

7. What future opportunities are emerging for the market?

8. How is technology influencing market development?

9. What is the current regulatory landscape for Immuno-Cell Therapy?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Immuno-Cell Therapy Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Immuno-Cell Therapy Segmentation

Immuno-Cell Therapy Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Immuno-Cell Therapy market size?

2. What is the projected growth forecast for the market?

3. What are the primary drivers behind market expansion?

4. Which challenges could hinder market growth?

5. Which regions are leading the Immuno-Cell Therapy market?

6. Who are the top companies operating in this space?

7. What future opportunities are emerging for the market?

8. How is technology influencing market development?

9. What is the current regulatory landscape for Immuno-Cell Therapy?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation